|
549 Pharmacists oppose
transfer of global sum to PCTs Pharmacy
representatives have opposed a proposal to transfer responsibility for
pharmacy remuneration in England from the Department of Health to primary
care trusts. NHS organisations have supported it and have indicated their
desire to be more closely involved with negotiations over payment for
services
PJ 2007;279:549
Full Text
549 Government defends the electronic
patient record against criticism from MPs The
Government has defended the much-criticised NHS Care Records Service
in its response to a House of Commons Health Committee report on the
electronic patient record by saying that a number of the committee's
suggestions are already being implemented
PJ 2007;279:549
Full Text
549 Greater public understanding of NICE needed Wider
discussion of the importance of assessing the cost-effectiveness of new medicines
is needed to improve public understanding on this issue, according to Andrew
Dillon, chief executive of the National Institute for Health and Clinical Excellence
PJ 2007;279:549
Full Text
549 Reduction in the retention fee increase
fails to quell dissent Disquiet over increases in pharmacists' retention fees for 2008 continues, in spite of the announcement of a £30 reduction in the proposed rise for practising pharmacists
PJ 2007;279:549
Full Text
550 Extra 14p per CD for four
months Pharmacy contractors in England are to get
an extra 14p for each Controlled Drug prescription they dispense for four months
in order to compensate them for losses caused by a change to the way prescriptions
were processed by the pricing office late in 2006
PJ 2007;279:550
Full Text
550 Minor ailment schemes need promotion, PSNC
tells inquiry National standardisation and promotion
of a scheme for managing minor ailments at NHS expense in community pharmacies
is essential, the Pharmaceutical Services Negotiating Committee has told a Parliamentary
inquiry into GP access and health improvement in primary care
PJ 2007;279:550
Full Text
550 NPA launches pseudoephedrine/ephedrine training
package Resources for pharmacists to provide awareness
training for pharmacy staff on pseudoephedrine and ephedrine sales have been
developed by the National Pharmacy Association
PJ 2007;279:550
Full Text
550 PSNC investigates impact on pharmacy contract
of PCT brand prescribing policies Figures are
being compiled by the Pharmaceutical Services Negotiating Committee to try to
find out how local primary care trust prescribing policies are distorting the
nationally negotiated pharmacy contract
PJ 2007;279:550
Full Text
551 Temporary registrants
unavoidable Little could be done to address regulators'
concerns that a recent European Directive on professional mobility and temporary
work might undermine patient safety, the Department of Health has said
PJ 2007;279:551
Full Text
551 UniChem to distribute Astellas immunosuppressants
in UK Astellas Pharma has appointed UniChem as
sole distributor for its tacrolimus products in the UK, following a spate of
complaints from pharmacists unable to obtain them in a timely manner
PJ 2007;279:551
Full Text
551 General Pharmaceutical Council As
The Journal went to press there was an expectation that the first reading of
the Health and Social Care Bill would take place on 15 November 2007
PJ 2007;279:551
Full Text
551 Rimonabant psychiatric risk The
anti-obesity agent rimonabant increases the risk of psychiatric adverse events,
a meta-analysis of all published randomised controlled trials of the medicine
suggests
PJ 2007;279:551
Full Text
551 Drugs achieve modest weight loss On
average, anti-obesity drugs achieve weight reductions of less than 5kg, a meta-analysis
suggests
PJ 2007;279:551
Full Text
552 Safety should be sole
criterion for reclassification Patient safety should
be the sole criterion when applications to reclassify prescription medicines
as pharmacy medicines are considered, the National Pharmacy Association has told
the Medicines and Healthcare products Regulatory Agency
PJ 2007;279:552
Full Text
552 Pharmacists in Scotland should separate
prescribing and dispensing Pharmacist independent
prescribers in Scotland will not normally be able to dispense prescriptions they
have written, according to regulations laid before the Scottish Parliament last
week
PJ 2007;279:552
Full Text
552 Peeress wants oral contraceptives to have
P-medicine status Questions are to be asked in
the House of Lords about making oral contraception available without prescription
from community pharmacies
PJ 2007;279:552
Full Text
552 P category considered in US Views
are being sought in the US on the possibility of establishing a behind-the-counter
class of medicines that can only be sold after personal intervention by a pharmacist
PJ 2007;279:552
Full Text
552 Sexual health advice Community
pharmacists can help young people understand the risks to their health from having
sex with new partners abroad, the fpa has said in response to research published
last week
PJ 2007;279:552
Full Text
553 Pharmacy double victory
in Scottish Health Awards Pharmacists won two of
this year's Scottish Health Awards presented at a ceremony in Edinburgh last
week
PJ 2007;279:553
Full Text
554 New HIV medicine set for
launch Patients with HIV who have been heavily
treated with antiretrovirals may be eligible for treatment with maraviroc, a
new type of medicine for HIV, available next week from Pfizer as Celsentri
PJ 2007;279:554
Full Text
554 Technician to lead WCPPE Lesley
Morgan has been appointed director of the Welsh Centre for Postgraduate Pharmaceutical
Education
PJ 2007;279:554
Full Text
R&D news
555 Prasugrel cuts CV deaths but raises bleeding
risk Prasugrel is associated with fewer ischaemic
events but more instances of bleeding than clopidogrel, a study of acute coronary
syndromes patients scheduled to undergo percutaneous coronary intervention suggests
PJ 2007;279:555
Full Text
555 First-in-class antidepressant prevents relapse A new type of antidepressant could help to prevent patients from relapsing. First-in-class agomelatine acts as an agonist at melatonergic MT1/MT2 receptors and as an antagonist at 5-HT2C receptors
PJ 2007;279:555
Full Text
555 Low-dose antihypertensive drugs could be
future AD therapy Valsartan has been shown to reduce
one of the neurological changes known to contribute to cognitive deterioration
in Alzheimer's disease (AD) in a recent animal study
PJ 2007;279:555
Full Text
555 Another anti-TNF tested for ankylosing spondylitis
and psoriatic arthritis patients Tumour necrosis factor inhibitor golimumab — being developed by Centocor and Schering-Plough — has shown promise in phase III studies of psoriatic arthritis and ankylosing spondylitis
PJ 2007;279:555
Full Text
556 Pitrakinra study indicates
potential of targeted therapy for asthma Pitrakinra,
a recombinant human interleukin-4 variant, may be effective in reducing the symptoms
of asthma, two phase IIa trials suggest
PJ 2007;279:556
Full Text
556 Early results show axitinib safe in renal
cancer Axitinib — a selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 — has shown promise for people with metastatic renal-cell cancer in a phase II study, published
PJ 2007;279:556
Full Text
556 Tezosentan fails to improve acute heart
failure survival Treatment with tezosentan, an
experimental medicine for acute heart failure, has failed to show improvements
in symptoms or survival in a 1,435-patient trial programme
PJ 2007;279:556
Full Text
556 Nicotine for levodopa dyskinesias Use
of nicotine or selective nicotine agonists could represent a useful strategy
for treating dyskinesias brought on by levodopa medicines in Parkinson's disease,
according to research published online
PJ 2007;279:556
Full Text
556 HIV vaccine not effective Merck and Co’s investigational HIV vaccine — V520 — has been shown to be ineffective at preventing HIV infection in individuals not infected with the virus at the start of a phase II study or at reducing the amount of virus within those who became infected throughout the course of the study
PJ 2007;279:556
Full Text
556 Gastric cancer survival Combination of tegafur, gimeracil and oteracil — under investigation as “S-1” in Japan — has been shown to improve survival in a study of 529 East Asians with stage II or III gastric cancer
PJ 2007;279:556
Full Text
556 Prucalopride for constipation Phase III research into novel 5-HT4-receptor agonist prucalopride has yielded favourable results for patients with chronic constipation
PJ 2007;279:556
Full Text
556 Anti-cancer virus Researchers
have engineered a tumour-selective poxvirus with systemic activity against cancer
cells
PJ 2007;279:556
Full Text |
The
Pharmaceutical Journal